3-[3-(piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists

Journal of Medicinal Chemistry

Volumn 42, Issue 24, 1999, Pages 4981-5001

  Russell, Michael G N ^a   Matassa, Victor G ^a   Pengilley, Roy R ^a   Van Niel, Monique B ^a   Sohal, Bindi ^a   Watt, Alan P ^a   Hitzel, Laure ^a   Beer, Margaret S ^a   Stanton, Josephine A ^a   Broughton, Howard B ^a   Castro, José L ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 FLUOROPHENYL) 2 [1 [3 [5 (1,2,4 TRIAZOL 4 YL) 3 INDOLYL]PROPYL] 4 PIPERIDINYLAMINO]ETHANOL; ANTIMIGRAINE AGENT; ELETRIPTAN; KETANSERIN; NARATRIPTAN; PIPERIDINE DERIVATIVE; RIZATRIPTAN; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; MIGRAINE;

ANIMALS; BIOLOGICAL AVAILABILITY; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INDOLES; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TRIAZOLES;

EID: 0033518190     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9910021     Document Type: Article

References (49)

1. Perry, C. M.; Markham, A. Sumatriptan: An Updated Review of its Use in Migraine. Drugs 1998, 55, 889-922.
2. 1B/D Agonists: Structure Activity Relationship and Pre-clinical Pharmacological Distinctions. Curr. Med. Chem. 1997, 4, 295-312.
3. Longmore, J.; Dowson, A.; Hill, R. G. Advances in Migraine Therapy - 5-HT Receptor Subtype-specific Agonist Drugs. Curr. Opin. CPNS Invest. Drugs 1999, 1, 39-53.
4. 1D Agonists. IDrugs 1999, 2, 37-43.
5. Connor, H. E.; Fenuik, W.; Beattie, D. T.; North, P. C.; Oxford, A. W.; Saynor, D. A.; Humphrey, P. P. A. Naratriptan: Biological Profile in Animal Models Relevant to Migraine. Cephalagia 1997, 17, 145-152.
6. 1D Receptor: Discovery of Compounds with Potential Anti-migraine Properties. J. Med. Chem. 1995, 38, 3566-3580.
7. 1D Receptors. J. Med. Chem. 1995, 38, 1799-1810.
8. Ngo, J.; Rabasseda, X.; Castañer, J. Eletriptan. Drugs Future 1997, 22, 221-224.
9. 1B/1D Receptor Agonists in Migraine. CNS Drugs 1998, 10, 271-286.
10. Cumberbatch, M. J.; Hill, R.; Hargreaves, R. J. Rizatriptan has Central Antinociceptive Effects Against Durally Evoked Responses. Eur. J. Pharmacol. 1997, 328, 37-40.
11. Goadsby, P. J.; Edvinsson, L. The Trigeminovascular System and Migraine: Studies Characterizing Cerebrovascular and Neuropeptide Changes Seen in Humans and Cats. Ann. Neurol. 1993, 33, 48-56.
12. Williamson, D. J.; Shepheard, S. L.; Hill, R. G.; Hargreaves, R. J. The Novel Antimigraine Agent Rizatriptan Inhibits Neurogenic Dural Vasodilation and Extravasation. Eur. J. Pharmacol. 1997, 328, 61-64.
13. Williamson, D. J.; Hargreaves, R. J.; Hill, R. G.; Shepheard, S. L. Sumatriptan Inhibits Neurogenic Vasodilation of Dural Blood Vessels in the Anaesthetized Rat - Intravital Microscope Studies. Cephalagia 1997, 17, 525-531.
14. 1D Receptor Subtypes. Trends Pharmacol. Sci. 1996, 17, 103-105.
15. 1Dβ Receptor Subtype in Human and Bovine Cerebral Arteries. Mol. Pharmacol. 1993, 44, 242-246.
16. 1Dα Serotonin Receptor Gene Expression in Trigeminal Ganglia: Implications for Antimigraine Drug Development. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3666-3669.
17. Bouchelet, I.; Cohen, Z.; Case, B.; Séguéla, P.; Hamel, E. Differential Expression of Sumatriptan-sensitive 5-hydroxytryptamine Receptors in Human Trigeminal Ganglia and Cerebral Blood Vessels. Mol. Pharmacol. 1996, 50, 219-223.
18. 1B-immunoreactivity within the Human Trigemino-cerebrovascular System: Implications for the Discovery of New Antimigraine Drugs. Cephalagia 1997, 17, 833-842.
19. Ottervanger, J. P.; Stricker, B. H. Ch. Cardiovascular Adverse Reactions to Sumatriptan. Cause for Concern? CNS Drugs 1995, 3, 90-98.
20. 1B Subtype. J. Med. Chem. 1997, 40, 0, 3497-3500.
21. 1D Receptor Subtype. Mol. Pharmacol. 1992, 42, 439-444.
22. Interestingly, 27 was shown to have a significantly shorter retention time than 28 on reverse-phase HPLC (see Experimental Section), again lending support to the theory that stabilization of an intramolecular H-bond is occurring in the latter.
23. Molecular modeling was performed in the gas phase (MOPAC, AM1 Hamiltonian, PRECISE convergence criteria) on analogues which, for ease of calculation, were truncated to leave a methyl group on the N atom of the piperidine ring. It showed that the low-energy conformers of 68 were such that intramolecular H-bonding was possible, and one of these conformers (the second-to-lowest in energy, being less than 0.5 kcal/mol above the global minimum and showing an RMS fit of the piperidine ring, the piperidine nitrogen substituent, the amino nitrogen, and the aromatic ring carbons of <1 Å) overlaid well onto the rigid, lowest energy conformer of 85 (Figure 1). For 79 there was insufficient energy differences between conformers that could have a H-bond and those that could not have a H-bond to say that this existed in a H-bonded conformation, whereas the low-energy conformers of 78 were such that intramolecular H-bonding was possible. Therefore, stabilization of the H-bonded conformer by the methyl substituent in 79 cannot be convincingly demonstrated on energetic grounds. Using the AM1/SM2.1 solvation model within AMSOL gave the same overall conclusions.
24. 1D Agonists: Potential New Treatment for Migraine without Cardiovascular Side Effects. J. Med. Chem. 1998, 41, 2180-2183.
25. The half-life was calculated from data over 3-6 h.
26. 1B Receptor. J. Med. Chem. 1999, 42, 677-690.
27. 1D Receptor Agonists as Potential Antimigraine Agents. J. Med. Chem. 1999, 42, 691-705.
28. 1D Receptor Agonist. J. Org. Chem. 1997, 62, 9192-9202.
29. 1D Receptor Agonist. J. Org. Chem. 1997, 62, 9192-9202.
30. 1D Receptor Agonist MK-0462 via a Pd-catalysed Coupling Reaction. Tetrahedron Lett. 1994, 35, 6981-6984.
31. Bradbury, B. J.; Baumgold, J.; Paek, R.; Kammula, U.; Zimmet, J.; Jacobson, K. A. Muscarinic Receptor Binding and Activation of Second Messengers by Substituted N-Methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides. J. Med. Chem. 1991, 34, 1073-1079.
32. Il'ina, I. G.; Ivanova, E. V.; Nozdrina, V. A.; Mikhalev, O. V.; Potapov, V. M. Synthesis of Electron Acceptors of the Picryl Series and their Chiral-optical Characteristics. Zh. Org. Khim. 1985, 21, 1922-1925.
33. Prelog, V.; Mutak, S. Stereoselectivity of 9,9′-Spirobifluorene Crown Ethers Towards α-Amino Alcohols. Helv. Chim. Acta 1983, 66, 2274-2278.
34. Castro, J. L.; Matassa, V. G. Mitsunobu-like Processes with a Novel Triphenylphosphine-Cyclic Sulfamide Betaine. J. Org. Chem. 1994, 59, 2289-2291.
35. O'Brien, P. M.; Sliskovic, D. R.; Blankley, C. J.; Roth, B. D.; Wilson, M. W.; Hamelehle, K. L.; Krause, B. R. Inhibitors of AcylCoA:Cholesterol O-Acyl Transferase (ACAT) as Hypocholesterolemic Agents. 8. Incorporation of Amide or Amine Functionalities into a Series of Disubstituted Ureas and Carbamates. Effects on ACAT Inhibition in Vitro and Efficacy in Vivo. J. Med. Chem. 1994, 37, 1810-1822.
36. Meyers, A. I.; Poindexter, G. S.; Brich, Z. Asymmetric Synthesis of (+)- or (-)-2-Methyloctanal via the Metalloenamines of Chiral Alkoxy Amines. J. Org. Chem. 1978, 43, 892-898.
37. Shih, Y.-E.; Wang, J.-S.; Chen, C.-T. Studies on Potential Antitumor Agents (III). Synthesis of 4-Arylcyclophosphamides. Heterocycles 1978, 9, 1277-1285.
38. Owens, A. P.; Williams, B. J.; Harrison, T.; Swain, C. J.; Baker, R.; Sadowski, S.; Cascieri, M. A. Phenylglycinol-Based NK1 Receptor Antagonists - Towards the Minimum Pharmacophore. Bioorg. Med. Chem. Lett. 1995, 5, 2761-2766.
39. Newman, M. S.; Edwards, W. M. New Reactions Involving Alkaline Treatment of 3-Nitroso-2-oxazolidones. J. Org. Chem. 1954, 19, 1840-1845.
40. Kornet, M. J.; Crider, A. M.; Magarian, E. O. Potential Long-acting Anticonvulsants. 2. Synthesis and Activity of Succinimides Containing an Alkylating Group on Nitrogen or at the 3-Position. J. Med. Chem. 1977, 20, 1210-1213.
41. Brown, N. C.; Gambino, J.; Wright, G. E. Inhibitors of Bacillus subtilis DNA Polymerase III. 6-(Arylalkylamino)uracils and 6-Anilinouracils. J. Med. Chem. 1977, 20, 1186-1189.
42. King, J. F.; Rathore, R.; Lam, J. Y. L.; Guo, Z. R.; Klassen, D. F. pH Optimization of Nucleophilic Reactions in Water. J. Am. Chem. Soc. 1992, 114, 3028-3033.
43. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701.
44. Creary, X.; Mehrsheikr-Mohammadi, M. E. Methylenecyclopropane Rearrangement as a Probe for Free Radical Substituent Effects. Effect of Sulfur in Various Oxidation States. J. Org. Chem. 1986, 51, 1110-1114.
45. Leo, A.; Hansch, C. Linear Free-Energy Relationships between Partitioning Solvent Systems. J. Org. Chem. 1971, 36, 1539-1544.
46. Tripos, Inc., St. Louis, Missouri.
47. Stewart, J. J. P. QCPE Program 455.
48. Hawkins G. D.; Lynch, G. C.; Giesen, D. J.; Rossi, I.; Storer, J. W.; Liotard, D. A.; Cramer, C. J.; Truhlar, D. G. AMSOL-Version 5.4, QCPE Program 606-Version 5.4.
49. 35S]GTPγS Binding Mediated by Human Muscarinic m1-m4 Receptors: Antagonist Studies. Br. J. Pharmacol. 1993, 109, 1120-1127.